ACTR8

Across TCGA pan-cancer cohorts, ACTR8 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ACTR8’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ACTR8 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ACTR8 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

LSCC, PDAC, and HNSC are the cancer types where ACTR8 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACTR8 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	All	All	+0.081	<.001	5	view →
PDAC	All	All	+0.215	<.001	4	view →
HNSC	All	All	+0.106	.011	4	view →
CCRCC	All	All	−0.084	.004	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ACTR8–LSCC

Open the LSCC breakdown →